Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Primary Purpose
Complicated Urinary Tract Infection
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
CXA-101
Ceftazidime
Sponsored by
About this trial
This is an interventional treatment trial for Complicated Urinary Tract Infection focused on measuring Complicated Urinary Tract Infection, Pyelonephritis, Antimicrobial, Cephalosporin, Intravenous
Eligibility Criteria
Inclusion Criteria:
- Males and females 18 to 90 years of age, inclusive.
- Pyuria (white blood cell [WBC] count > 10/µL in unspun urine or ≥ 10 per high power field in spun urine)
Clinical signs and/or symptoms of cUTI, either of:
a. Pyelonephritis, as indicated by both of the following: i. Fever (oral temperature ≥ 37.8°C); ii. Flank pain or costovertebral angle tenderness;
OR
b. Complicated lower UTI, as indicated by both of the following: i. At least one of the following new or worsening symptoms:
- Dysuria;
- Frequency;
- Suprapubic pain;
- Urgency
ii. At least one of the following complicating factors:
- Male gender;
- Current bladder instrumentation or indwelling urinary catheter that is expected to be removed during the course of IV study drug administration;
- Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
- Urogenital surgery within 7 days preceding administration of the first dose of study drug;
- Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.
Exclusion Criteria
- Documented history of any hypersensitivity or allergic reaction to any β-lactam antibacterial
- Concomitant infection requiring systemic antibacterial therapy in addition to IV study drug therapy at the time of randomization. Drugs with only gram-positive activity (e.g. vancomycin, linezolid) are allowed
- Complete, permanent obstruction of the urinary tract
- Confirmed (at time of randomization) fungal urinary tract infection (with ≥ 103 fungal CFU/mL)
- Suspected or confirmed perinephric or intrarenal abscess
- Suspected or confirmed prostatitis
- Known ileal loop or vesico-ureteral reflux
- Women who are pregnant or nursing
Sites / Locations
- Healthcare Partners Medical Group
- Compass Research, LLC
- Atlanta Institute for Medical Research, Inc.
- Infectious Disease of Indiana, PSC
- Mississippi Medical Research, LLC
- Great Falls Clinic, LLP
- Remington-Davis, Inc. Clinical Research
- Kreiskrankenhaus Backnang
- URO Forschungs GmbH
- Uniklinikum Giessen
- Evangelisches Krankenhaus Giessen Urologie
- Universitätsklinikum Schleswig Holstein Campus Lübeck
- Brüderkrankenhaus St. Josef Paderborn
- Urologische Klinik Dr. Castringius München-Planegg
- Samodzielny Publiczny Szpital Kliniczny nr 4 Katedra i Klinika Nefrologii
- Wojewódźki Szpital Specjalistyczny nr 1 Oddział Chorób Wewnętrznych
- Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych
- Szpital Kliniczny Dzieciątka Jezus-Centrum Leczenia Obrażeń Klinika Urologii Ogólnej, Onkologicznej Czynnościowej
- Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych
- Wojewódźki Szpital Specjalistyczny Oddział Nefrologiczny
- Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
CXA-101
Ceftazidime
Outcomes
Primary Outcome Measures
Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population
Microbiological response is eradication for each baseline pathogen
Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.
Microbiological response is eradication for each baseline pathogen
Secondary Outcome Measures
Full Information
NCT ID
NCT00921024
First Posted
June 12, 2009
Last Updated
September 21, 2018
Sponsor
Cubist Pharmaceuticals LLC
1. Study Identification
Unique Protocol Identification Number
NCT00921024
Brief Title
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Official Title
A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
June 30, 2009 (Actual)
Primary Completion Date
February 25, 2010 (Actual)
Study Completion Date
March 11, 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cubist Pharmaceuticals LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of intravenous CXA 101 and comparator in complicated urinary tract infection
Detailed Description
This is a Phase 2, multicenter, prospective, randomized, double-blind, comparative efficacy and safety study of IV CXA 101 versus IV ceftazidime for 7 to 10 days.
Subjects are followed up 6 to 9 days after the last dose of study drug to assess clinical signs and symptoms of infection. A Late Follow Up evaluation (21 to 28 days after the last dose of study drug) occurs for those subjects who respond to therapy. The primary assessment of effectiveness is the microbiological response (the eradication at post-therapy of the infectious organism identified at the start of study). An additional assessment of efficacy includes the overall clinical response, which is described as cured, improved, or failed. Safety assessments include the incidence of adverse events throughout the study, clinical laboratory tests (hematology, serum chemistry, and urinalysis) and physical examinations at the start of the study and post-therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Complicated Urinary Tract Infection
Keywords
Complicated Urinary Tract Infection, Pyelonephritis, Antimicrobial, Cephalosporin, Intravenous
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
129 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
CXA-101
Arm Title
2
Arm Type
Active Comparator
Arm Description
Ceftazidime
Intervention Type
Drug
Intervention Name(s)
CXA-101
Intervention Description
intravenous
Intervention Type
Drug
Intervention Name(s)
Ceftazidime
Intervention Description
intravenous
Primary Outcome Measure Information:
Title
Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population
Description
Microbiological response is eradication for each baseline pathogen
Time Frame
TOC; 6-9 days after last study drug administration
Title
Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.
Description
Microbiological response is eradication for each baseline pathogen
Time Frame
TOC; 6-9 days after last study drug administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females 18 to 90 years of age, inclusive.
Pyuria (white blood cell [WBC] count > 10/µL in unspun urine or ≥ 10 per high power field in spun urine)
Clinical signs and/or symptoms of cUTI, either of:
a. Pyelonephritis, as indicated by both of the following: i. Fever (oral temperature ≥ 37.8°C); ii. Flank pain or costovertebral angle tenderness;
OR
b. Complicated lower UTI, as indicated by both of the following: i. At least one of the following new or worsening symptoms:
Dysuria;
Frequency;
Suprapubic pain;
Urgency
ii. At least one of the following complicating factors:
Male gender;
Current bladder instrumentation or indwelling urinary catheter that is expected to be removed during the course of IV study drug administration;
Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
Urogenital surgery within 7 days preceding administration of the first dose of study drug;
Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.
Exclusion Criteria
Documented history of any hypersensitivity or allergic reaction to any β-lactam antibacterial
Concomitant infection requiring systemic antibacterial therapy in addition to IV study drug therapy at the time of randomization. Drugs with only gram-positive activity (e.g. vancomycin, linezolid) are allowed
Complete, permanent obstruction of the urinary tract
Confirmed (at time of randomization) fungal urinary tract infection (with ≥ 103 fungal CFU/mL)
Suspected or confirmed perinephric or intrarenal abscess
Suspected or confirmed prostatitis
Known ileal loop or vesico-ureteral reflux
Women who are pregnant or nursing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmad Haidar, MD
Organizational Affiliation
Mississippi Medical Research, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ryszard Gellert, MD
Organizational Affiliation
Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych i Pododdział Nefrologiczny
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Florian Wagenlehner, MD
Organizational Affiliation
Uniklinikum Giessen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Healthcare Partners Medical Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90015
Country
United States
Facility Name
Compass Research, LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Atlanta Institute for Medical Research, Inc.
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Facility Name
Infectious Disease of Indiana, PSC
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46280
Country
United States
Facility Name
Mississippi Medical Research, LLC
City
Picayune
State/Province
Mississippi
ZIP/Postal Code
39466
Country
United States
Facility Name
Great Falls Clinic, LLP
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Remington-Davis, Inc. Clinical Research
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Facility Name
Kreiskrankenhaus Backnang
City
Backnang
ZIP/Postal Code
71522
Country
Germany
Facility Name
URO Forschungs GmbH
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
Uniklinikum Giessen
City
Giessen
ZIP/Postal Code
35392
Country
Germany
Facility Name
Evangelisches Krankenhaus Giessen Urologie
City
Giessen
ZIP/Postal Code
35398
Country
Germany
Facility Name
Universitätsklinikum Schleswig Holstein Campus Lübeck
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Brüderkrankenhaus St. Josef Paderborn
City
Paderborn
ZIP/Postal Code
33098
Country
Germany
Facility Name
Urologische Klinik Dr. Castringius München-Planegg
City
Planegg
ZIP/Postal Code
82152
Country
Germany
Facility Name
Samodzielny Publiczny Szpital Kliniczny nr 4 Katedra i Klinika Nefrologii
City
Lublin
ZIP/Postal Code
20-954
Country
Poland
Facility Name
Wojewódźki Szpital Specjalistyczny nr 1 Oddział Chorób Wewnętrznych
City
Tychy
ZIP/Postal Code
43-100
Country
Poland
Facility Name
Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych
City
Warszawa
ZIP/Postal Code
01-809
Country
Poland
Facility Name
Szpital Kliniczny Dzieciątka Jezus-Centrum Leczenia Obrażeń Klinika Urologii Ogólnej, Onkologicznej Czynnościowej
City
Warszawa
ZIP/Postal Code
02-005
Country
Poland
Facility Name
Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych
City
Warszawa
ZIP/Postal Code
03-401
Country
Poland
Facility Name
Wojewódźki Szpital Specjalistyczny Oddział Nefrologiczny
City
Wrocław
ZIP/Postal Code
51-124
Country
Poland
Facility Name
Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ
City
Zamość
ZIP/Postal Code
22-400
Country
Poland
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Learn more about this trial
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
We'll reach out to this number within 24 hrs